BioSpace News Archive

Targeted therapies such as immunotherapy harness the potential of immune system to selectively target the cancer cells.

Known as the City of Hope patient, he is the fourth patient in the world and the oldest to go into long-term remission of HIV without antiretroviral therapy for over a year after receiving stem cells from a donor with a rare genetic mutation.

Mercury Medical recently received MDR CE Mark Certification for their CPR manual resuscitation line.

RemSleep Holdings Inc. is pleased to announce that the company’s common shares will begin trading on the OTCQB Market as of the opening of the market on , July 27, 2022.

Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has received approvals from the U.S. and EU regulatory authorities to manufacture JYNNEOS®/IMVANEX® smallpox and monkeypox vaccine at the Company’s fill and finish facility in Denmark.

Today, the U.S. Food and Drug Administration issued a draft guidance to help ensure that information is available to patients and health care professionals to clearly communicate the benefits and risks of LASIK devices.

AKSO Biopharmaceutical, Inc. (“AKSO”), a global biopharmaceutical company with an innovative and comprehensive approach to treat cancer, autoimmune disease, and genetic disorder, announced the publication in the Journal of Experimental Medicine of preclinical data demonstrating that AKSO’s late preclinical stage molecule AB001 effectively inhibits growth of Multiple Myeloma (“MM”) and Diffuse Large B Cell Lymphoma (“DLBCL”) in mice.

According to the report, the global antithrombin treatment market was valued at US$ 0.50 Bn in 2022 and is anticipated to expand at a CAGR of 5.3% from 2022 to 2030.

The global cell culture media, sera, and reagents market was valued at US$ 4.9 Bn in 2022 and is anticipated to expand at a CAGR of 5.7% from 2022 to 2030.

The global clinical laboratory services market was valued at US$ 232.6 Bn in 2022 and is anticipated to expand at a CAGR of 6.3% from 2022 to 2030.